A comparative study of the adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica in oral and nasal immunization with virus capsid antigens

被引：4

作者：

Lee, Jae Young ^{[1
]}

Xu, Mei Ling ^{[1
]}

Kim, Hyoung Jin ^{[1
]}

Kang, Hyun Ah ^{[2
]}

Kim, Hong-Jin ^{[1
]}

机构：

[1] Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea

[2] Chung Ang Univ, Dept Life Sci, Coll Nat Sci, Seoul 156756, South Korea

来源：

BIOTECHNOLOGY LETTERS | 2013年 / 35卷 / 11期

关键词：

Hansenula polymorpha; Influenza virus; Mucosal immunization; Papillomavirus; Virus-like particles; HEAT-LABILE TOXIN; ESCHERICHIA-COLI; DOUBLE-BLIND; PARTICLES; VACCINES; MUCOSAL; PROTEIN;

D O I：

10.1007/s10529-013-1273-8

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

The adjuvanticity of Hansenula polymorpha, Saccharomyces cerevsiae and Yarrowia lipolytica were compared for oral and nasal immunization with virus capsid antigens. Mice were immunized orally with human papillomavirus type 16 L1 virus-like particles (HPV16 L1 VLPs), or intra-nasally with formalin-inactivated influenza A virus (FIV), in combination with one or other yeast. Mice receiving HPV16 L1 VLPs combined with H. polymorpha had a significantly higher titer for serum anti-HPV16 L1 IgG and neutralizing activity than those receiving HPV16 L1 VLPs combined with either of the other two yeasts. Also, mice receiving FIV combined with H. polymorpha had not only a markedly higher anti-influenza A virus IgG titer but also a higher survival rate after a potentially lethal influenza A virus challenge. We suggest that H. polymorpha thus will be useful for enhancing immune responses in mucosal immunizations.

引用

页码：1881 / 1888

页数：8

共 25 条

[11] Inflammatory cytokines and antigen presenting cell activation [J].

Murtaugh, MP ;

Foss, DL .

VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2002, 87 (3-4) :109-121

[12]

Oyewumi MO, 2010, EXPERT REV VACCINES, V9, P1095, DOI [10.1586/erv.10.89, 10.1586/ERV.10.89]

[13] New insights in mucosal vaccine development [J].

Pavot, Vincent ;

Rochereau, Nicolas ;

Genin, Christian ;

Verrier, Bernard ;

Paul, Stephane .

VACCINE, 2012, 30 (02) :142-154

[14]

REED L. J., 1938, AMER JOUR HYG, V27, P493

[15] Approaches for enhancing oral bioavailability of peptides and proteins [J].

Renukuntla, Jwala ;

Vadlapudi, Aswani Dutt ;

Patel, Ashaben ;

Boddu, Sai H. S. ;

Mitra, Ashim K. .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2013, 447 (1-2) :75-93

[16] Stabilization of human papillomavirus virus-like particles by non-ionic surfactants [J].

Shi, L ;

Sanyal, G ;

Ni, A ;

Luo, Z ;

Doshna, S ;

Wang, B ;

Graham, TL ;

Wang, N ;

Volkin, DB .

JOURNAL OF PHARMACEUTICAL SCIENCES, 2005, 94 (07) :1538-1551

[17]

Slütter B, 2008, J DRUG TARGET, V16, P1, DOI [10.1080/10611860701637966, 10.1080/10611860701637966 ]

[18] A direct comparison of human papillomavirus type 16 L1 particles reveals a lower immunogenicity of capsomeres than viruslike particles with respect to the induced antibody response [J].

Thoenes, Nadja ;

Herreiner, Anna ;

Schaedlich, Lysann ;

Piuko, Konrad ;

Mueller, Martin .

JOURNAL OF VIROLOGY, 2008, 82 (11) :5472-5485

[19] ELECTROPOSITIVELY CHARGED FILTERS FOR THE RECOVERY OF YEASTS AND BACTERIA FROM BEVERAGES [J].

THOMAS, DS .

JOURNAL OF APPLIED BACTERIOLOGY, 1988, 65 (01) :35-41

[20] Equine Rhinitis A Virus and Its Low pH Empty Particle: Clues Towards an Aphthovirus Entry Mechanism? [J].

Tuthill, Tobias J. ;

Harlos, Karl ;

Walter, Thomas S. ;

Knowles, Nick J. ;

Groppelli, Elisabetta ;

Rowlands, David J. ;

Stuart, David I. ;

Fry, Elizabeth E. .

PLOS PATHOGENS, 2009, 5 (10) :e1000620

← 1 2 3 →